HIV treatment-naïve study to evaluate safety and efficacy of a fixed dose combination (FDC) containing GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) in HIV-1 infected, antiretroviral treatment naïve-adult subjects. This is a 96 week study.
Who may be Eligible
Adults age 18 years or older; antiretroviral treatment naïve (=10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection) except the use for PrEP or PEP up to one month prior to screening; Plasma HIV-1 RNA levels =500 copies/mL at the screening visit; normal ECG; normal maintenance lab values; not pregnant or nursing or planning to become pregnant during the trial or considering fathering a child while on treatment. Male subjects must agree to refrain from using sperm donation from first study drug dose until at least 90 days following the last study drug dose; female subjects who utilize hormonal contraceptive as one of their birth control methods must hve used the same method for at least threemonths prior to study dosing; no chronic hepatitis B virus (HBV) infection as determined by either Positive HBV surface antibody, regardless of HBV surface antigen status, at the screening visit; negative screening test for HLA-B*5701 allele; screening genotype report must show sensitivity to FTC, TFG, 3TC, and ABC; no active serious infections other than HIV; no participation in other clinical trials; not taking one of a list of disallowed medications; no documented resistance to any of the study agents at any time in the past; serum amylase =5 x ULN (subjects with serum amylase >5 ULN will remain eligible if serum lipase is =5 x ULN); adequate renal function; life expentancy >1 year; screening genotype report must show sensitivity to FTC, TFV, 3TC, and ABC.